Newly Discovered Late Clinical Stage Biopharma Vendor with Potentially Revolutionary Breakthroughs & 4 Growing Companies to C...
November 19 2014 - 7:00AM
InvestorsHub NewsWire
Fuse Science, Inc. (OTCBB:
DROP) is a life sciences company which has developed and
maintains the rights to sublingual and transdermal delivery systems
for the efficient delivery to humans of energy, medicines, vitamins
and minerals.
The company recently announced a restructuring that could lead to a
new business direction. Get the details by reading this report:
http://bit.ly/-DROP-AnalystBrief
GNCC Capital, Inc. (OTCBB:
GNCP) is a Diversified Holding Company which at present has
Revenue Generating, Cash Positive and Profitable subsidiary
companies which are engaged in the owning and operation of Adult
Social Gaming Arcades based in South Florida. The Company also has
significant assets in Gold & Silver Mining Exploration in
Arizona.
GNCP has taken some restructuring steps intended to bolster
specific existing operations. Read about these plans and actions in
the report that follows: http://bit.ly/-GNCP-AnalystBrief
NanoViricides, Inc. (NYSE-MKT:
NNVC) is a development stage company that is creating special
purpose nanomaterials for antiviral therapy. The Company's novel
nanoviricide(R) class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them.
NNVC Has updated investors with information on some of its pipeline
drugs and recent financial highlights. Read about here in this
report: http://bit.ly/-NNVC-AnalystBrief
Sigma Labs, Inc. (OTCQB:
SGLB) through its wholly-owned subsidiary B6 Sigma, Inc.,
develops and engineers advanced, in-process, non-destructive
quality inspection systems for commercial firms worldwide seeking
productive solutions for metal-based additive manufacturing or 3D
printing, and other advanced manufacturing technologies.
The company has released information on product development and
financial results for the period ended 9-30-14. Get the details
when you read this report: http://bit.ly/-SGLB-AnalystBrief
Our new alert CANF was by far the #1 gainer in the entire AMEX
exchange until about 3-3:15 PM when it became obvious that after we
hit the 75% gains mark at $4.30/share, profit taking dominated the
remainder of the trading session. Congrats to those who obviously
pulled profits along the way.
In our original report below we mentioned Roth Capital Analyst
Report had issued a $15 price target last year. That was actually
upgraded based on clinical results afterward to a $28 target.
Small Cap IR was the first firm to notify its members of CANF on
11-18-2014 with a full due diligence report before market open.
An analyst report which includes an overview of the company,
financial and competitive analysis, analyst recommendation and
price target can be viewed in its entirety by using the link below.
There is no cost obligation required to view this report.
http://bit.ly/-CANF-AnalystValuation
About Small Cap IR
Once you have read our reports written by financial analysts you
will understand that we make every effort to provide informative
equity research reports for interested parties.
3rd party chartered financial analysts (CFA’s) provide a
straightforward assessment of the profiled company and have pledged
to remain free of influence when writing research reports. They
include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis
by a 3rd party research analyst. However, we are only human and are
prone to make mistakes. If you notice any errors or omissions,
please notify us below. We do not engage in high frequency
trading.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team,
or wish to learn more about our services, please contact us at
editor@smallcapir.com. For any urgent concerns or inquiries please
contact us at editor@smallcapir.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
Source: Small Cap IR
Contact: editor@smallcapir.com
GNCC Capital (CE) (USOTC:GNCP)
Historical Stock Chart
From Jul 2024 to Aug 2024
GNCC Capital (CE) (USOTC:GNCP)
Historical Stock Chart
From Aug 2023 to Aug 2024